- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Tomosynthesis Market Sees Competition with GE FDA Approval
GE’s SenoClaire breast tomosynthesis solution will join Hologic, the only other vendor with FDA approval for 3D mammography.
Three-dimensional breast imaging options are finally expanding, as GE Healthcare announced today United States Food and Drug Administration (FDA) approval of SenoClaire, GE’s new breast tomosynthesis solution.
GE collaborated with Massachusetts General Hospital to develop the SenoClaire technology, which uses a low-dose short X-ray sweep around the positioned breast with nine exposures taken in a “step-and-shoot” manner, the release said. The technology eliminates potential motion from the tube, which helps to reduce blur and increase image quality, according to the release.
With concern growing over radiation levels associated with screening mammography, GE ensured the SenoClaire technology would not have increased radiation from a 2D standard mammogram, the release said.
SenoClaire is compatible with Centricity PACS with Universal Viewer and supports the DICOM standard that can be read by capable PACS vendors, the release reported.
“3D breast screening technology helps clinicians uncover small cancers which can be a limiting factor in standard 2D mammography. As a radiologist, it’s important to offer technology like this for patients that produces higher image quality without increasing dose,” Murray Rebner, MD, FACR, a professor of diagnostic radiology and molecular imaging and director of the division of breast imaging and intervention at Beaumont Hospital, Royal Oak, Mich. “We believe this technology can have a significant impact on helping clinicians to identify breast cancer.”[[{"type":"media","view_mode":"media_crop","fid":"27493","attributes":{"alt":"GE SenoClaire ","class":"media-image media-image-right","id":"media_crop_1099140026163","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2691","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 140px; width: 175px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]
GE will be rivaling the market dominator Hologic, who has owned the tomosynthesis market since 2011. Siemens is also looking to enter the market and is awaiting approval after submitting a premarket approval application in July.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography Study: AI Improves Breast Cancer Detection and Reduces Reading Time with DBT
April 3rd 2024An emerging artificial intelligence (AI) model demonstrated more than 12 percent higher specificity and reduced image reading time by nearly six seconds in comparison to unassisted radiologist interpretation of digital breast tomosynthesis (DBT) images.
